Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer

In this study, Adebrelimab combined with NALIRIFOX conversion therapy was performed in subjects with locally advanced pancreatic cancer to evaluate the efficacy and safety of conversion therapy with immunotherapy combined with chemotherapy, followed by different treatment methods such as surgery, continued conversion therapy, and advanced systemic therapy according to different transformation outcomes, to improve the survival benefit of subjects with locally advanced pancreatic cancer.

Trial Details

NCT ID

NCT06475326

Phase

PHASE2

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Adebrelimab
Oxaliplatin 100 MG
Irinotecan liposome
Calcium Folinate
Fluorouracil

Locations (sample)

Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

Age 18-75 years old;
Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (preferably histologically confirmed);
Judged by the investigator to be unresectable locally advanced (unresectable criteria refer to the guidelines for the diagnosis and treatment of pa…
Total bilirubin ≤ 2 mg/dL (subjects with bile duct stents can be enrolled if bilirubin ≤ 2 mg/dL and no cholangitis after stent placement);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →